ProtaGene

Activities: Manufacturing Research & Development Analysis

Trending Articles

  1. Rousselot to unveil gelatin prototypes for innovative medical device development at COMPAMED 2025 Rousselot, Darling Ingredients’ premier collagen and gelatin brand, will participate in COMPAMED 2025, November 17-20, 2025, in Düsseldorf, Hall 8, Booth AK14
  2. Agility, scale and trust: the outsourcing model driving pharma forward Outsourcing in the pharmaceutical industry has long been viewed as a matter of convenience and a way to ease short-term capacity pressures or delay the decision to invest in...
  3. Gerresheimer boosts Wertheim site with new production facility The new production hall will focus on RTF vials and innovative EZ-fill Smart packaging platform, with a total investment volume of around EUR €30 million
  4. Designing and developing bioconjugates for clinical success Abzena shares new insights and technologies to accelerate safe and effective ADC development
  5. PCI Pharma Services PCI Pharma Services: Your bridge between life-changing therapies and patients.

Upcoming event

CPHI Frankfurt 2025

28–30 October 2025 | Exhibition | Frankfurt, Germany See all

Related Content

Finance

New capital strengthens ProtaGene's advanced analytical leadership in the biologics and CGT markets

ProtaGene GmbH, a leading global contract research organization (CRO) dedicated to advanced analytics for biologics and cell and gene therapies, announces additional investment from Ampersand Capital Partners
Regulatory

Confronting molecular bioanalysis challenges in gene therapy development

As the gene therapy sector continues to mature, regulators’ expectations for more robust product understanding are growing. It’s exciting to be part of today’s gene therapy development community; however, three issues are at the top of the industry’s mind—the regulatory landscape, critical molecular bioanalysis considerations (biodistribution, transgene expression, and vector shedding), and assay-related challenges
Manufacturing

Navigating CMC challenges in NBE and therapeutic antibody development

Insights by Dr Thomas Flad, Senior Director of Solutions & Innovation at ProtaGene, as he poses solutions to the difficulty matching analytical resources with analytical demands
Manufacturing

Join ProtaGene and ADRES for a joint webinar on regulatory and analytical aspects of comparability in biologics development

From research through product commercialisation, ProtaGene provides advanced, integrated, and complete protein and gene analytic capabilities
Drug Delivery

ProtaGene appoints new scientific and commercial leadership

The move is set to support evolving needs of biologic and cell and gene therapy innovators
Drug Delivery

ProtaGene appoints new Chief Executive Officer

Kaiser will drive the continued innovation and growth strategy for the company's advanced analytical services
Analysis

Unify Operations re-brand as ProtaGene

ProtaGene provide analytical services to the biopharmaceutical and gene therapy development sectors
Subscribe now